

## Overcoming Disease Recurrence and Treatment Resistance in HER2-Positive Metastatic Tumors – Tweertorial #3 References

### Tweet 4

Oh D-Y, Bang Y-J. HER2-targeted therapies — a role beyond breast cancer. *Nat Rev Clin Oncol*. 2020;17(1):33-48. doi:10.1038/s41571-019-0268-3

Pillai RN, Behera M, Berry LD, et al. HER2 mutations in lung adenocarcinomas: a report from the Lung Cancer Mutation Consortium. *Cancer*. 2017;123(21):4099-4105. doi:10.1002/cncr.30869

Zhao J, Xia Y. Targeting HER2 alterations in non–small-cell lung cancer: a comprehensive review. *JCO Precision Oncology*. 2020;(4):411-425. doi:10.1200/po.19.00333

### Tweet 5

Li BT, Smit EF, Goto Y, et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. *N Engl J Med*. 2021;doi:10.1056/NEJMoa2112431

Liu Z, Wu L, Cao J, et al. Clinical characterization of ERBB2 exon 20 insertions and heterogeneity of outcomes responding to afatinib in Chinese lung cancer patients. *Onco Targets Ther*. 2018;11:7323-7331. doi:10.2147/OTT.S173391

Zhao J, Xia Y. Targeting HER2 alterations in non–small-cell lung cancer: a comprehensive review. *JCO Precision Oncology*. 2020;(4):411-425. doi:10.1200/po.19.00333

### Tweet 6

Pillai RN, Behera M, Berry LD, et al. HER2 mutations in lung adenocarcinomas: a report from the Lung Cancer Mutation Consortium. *Cancer*. 2017;123(21):4099-4105. doi:10.1002/cncr.30869

Riudavets M, Sullivan I, Abdayem P, Planchard D. Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations. *ESMO Open*. 2021;6(5):100260. doi:10.1016/j.esmoop.2021.100260

### Tweet 7

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Non-Small Cell Lung Cancer (v1.2022). Updated December 7, 2021. Accessed January 10, 2022. [https://www.nccn.org/professionals/physician\\_gls/pdf/nscl.pdf](https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf)

### Tweet 9

Li BT, Shen R, Buonocore D, et al. Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. *J Clin Oncol*. 2018;36(24):2532-2537. doi:10.1200/JCO.2018.77.9777

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Non-Small Cell Lung Cancer (v1.2022). Updated December 7, 2021. Accessed January 10, 2022. [https://www.nccn.org/professionals/physician\\_gls/pdf/nscl.pdf](https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf)

Smit EF, Nakagawa K, Nagasaka M, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01. *J Clin Oncol*. 2020;38(15\_suppl):9504-9504. doi:10.1200/JCO.2020.38.15\_suppl.9504

#### **Tweet 11**

Li BT, Shen R, Buonocore D, et al. Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. *J Clin Oncol*. 2018;36(24):2532-2537. doi:10.1200/JCO.2018.77.9777

#### **Tweet 13**

ClinicalTrials.gov. DS-8201a in human epidermal growth factor receptor 2 (HER2)-expressing or -mutated non-small cell lung cancer (DESTINY-Lung01). NCT03505710. Updated July 1, 2021. Accessed November 16, 2021. <https://clinicaltrials.gov/ct2/show/NCT03505710>

Li BT, Smit EF, Goto Y, et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. *N Engl J Med*. 2021;doi:10.1056/NEJMoa2112431

#### **Tweet 14**

ClinicalTrials.gov. Trastuzumab deruxtecan in participants with HER2-mutated metastatic non-small cell lung cancer (NSCLC) (DESTINY-LUNG02). NCT04644237. Updated July 12, 2021. Accessed November 16, 2021. <https://clinicaltrials.gov/ct2/show/NCT04644237>

#### **Tweet 15**

ClinicalTrials.gov. Basket study of tucatinib and trastuzumab in solid tumors with HER2 alterations. NCT04579380. Updated November 9, 2021. Accessed November 17, 2021. <https://clinicaltrials.gov/ct2/show/NCT04579380>

Reck M, Ramos J, Tan S, Stinchcombe T. P47.01 SGNTUC-019: Phase 2 study of tucatinib and trastuzumab in solid tumors: lung cancer cohorts (clinical trial in progress). *J Thorac Oncol*. 2021;16(10):S1096. doi:10.1016/j.jtho.2021.08.494

## Glossary

ADC, antibody-drug conjugate  
adenoca, adenocarcinoma  
a, advanced  
AE, adverse event  
ALT, alanine aminotransferase  
AST, aspartate aminotransferase  
DCR, disease control rate  
DOR, duration of response  
ECOG, Eastern Cooperative Group  
F, female  
HCP, health care provider  
HER2, human epidermal growth factor receptor 2  
ILD, interstitial lung disease  
LC, lung cancer  
m, metastatic  
mDOR, median duration of response  
mos, months  
mOS, median overall survival  
mPFS, median progression-free survival  
NCCN, national comprehensive cancer network  
NSCLC, non-small cell lung cancer  
ORR, objective response rate  
OS, overall survival  
PFS, progression-free survival  
Ph, Phase  
PS, performance status  
Pt(s), patient(s)  
QOL, quality of life  
SCC, squamous cell carcinoma  
T-DM1, trastuzumab emtansine  
T-DXd, trastuzumab deruxtecan  
TRAE, treatment-related adverse events  
Tx, treatment/ therapy, therapies  
w/, with  
w/o, without